cnv

CNV-2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels.

Raxatrigine (CNV 1014802) has been investigated for the treatment of Bipolar Disorder and Bipolar Depression.

Mecamylamine hydrochloride (Mevasin) is a nicotinic antagonist, used as a ganglionic blocker in hypertension.

Raxatrigine hydrochloride is a state-dependent sodium channel blocker and a Nav1.7 sodium channel inhibitor.

SC 46944 is a highly potent human renin inhibitor.

CNV-dopamine is a photoactivatable, selective agonist of the D2 receptor (D2 receptor). It activates the D2 receptor, triggering G protein-coupled inwardly rectifying potassium (GIRK) currents. CNV-dopamine shows potential for research in diseases such as Parkinson's disease and addiction.

CNV Dopamine is a carboxynitroveratryl (CNV)-caged dopamine; releases dopamine upon ultraviolet light stimulation (365 nm). Induces dopaminergic currents upon photolysis in brain slices expressing wild-type or GFP-labeled D2receptors. Displays no decrease in current (rundown) with UV light flash duration of up to 100 ms. Pharmacologically inactive prior to photolysis.

ω-Conotoxin CnVIIA, a 27-amino-acid neuropeptide toxin, serves as an N-type calcium current blocker [1].

Tau conotoxin CnVA, a small peptide found in the venom of Conus consors (cone snail), is a member of the T1 cone snail peptide superfamily. It demonstrates high selectivity for the somatostatin sst3 receptor with a Ki value of 1.5 µM. Tau conotoxin CnVA is unique as the only known toxin interacting with this subfamily of G protein-coupled receptors (GPCR). This compound is useful for research related to diseases associated with the sst3 receptor, such as pancreatic cancer or pituitary adenomas.

Fmoc-Nva-OH is an amino acid derivative and has a wide range of applications in life science related research.

Boc-Nva-OH is an amino acid derivative and has a wide range of applications in life science related research.

IMS2186 is a reagent with activity of antichoroidal neovascularization (CNV). IMS2186 could arrest cancer cell cycle in G2/M phase, result in exerting anti-proliferation and anti-angiogenesis effects. IMS2186 reduces the amount of eye leakage and diseased cells with no intraocular toxicity.

SH-11037 is a novel potent seh inhibitor, effectively blocking key angiogenic properties of human retinal endothelial cells (hrecs), inhibiting choroidal sprouting and significantly suppressing cnv lesion volume

Bevasiranib, a siRNA, is specifically engineered to suppress the expression of genes responsible for the production of vascular endothelial growth factor (VEGF), a critical factor in the development of choroidal neo-vascularization (CNV), which precedes wet age-related macular degeneration (wet AMD).

Bevasiranib sodium, an siRNA compound, targets and silences the genes responsible for producing vascular endothelial growth factor (VEGF). The suppression of VEGF, a critical factor in the development of choroidal neo-vascularization (CNV), aims to thwart the progression to wet age-related macular degeneration (wet AMD).

Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. It reduces the release of cytokines IL-8 and IL-6 in SKOV3 cells and blocks tumor cell migration triggered by LPA. In Matrigel plug and CNV models, Lpathomab decreases angiogenesis. In the CCI mouse model, it inhibits brain injury. This compound can be utilized for research on brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: HumanIgG1kappa, Isotype Control.

TAT-N24 is a cell-penetrating TAT peptide that functions as a p55PIK signaling inhibitor. By suppressing the HIF-1α/NF-κB signaling pathway in corneal sutures (CS), TAT-N24 can treat corneal neovascularization (CNV) and ocular inflammation. Additionally, TAT-N24 inhibits the formation of corneal neovascularization.